Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adventrx to acquire SD Pharma
Under the terms of the agreement, Adventrx will issue, and SD Pharma stockholders will receive, approximately 2,100,000 shares of Adventrx common stock. The agreement and plan of merger
Under the terms of the agreement, Adventrx will issue, and SD Pharma stockholders will receive, approximately 2,100,000 shares of Adventrx common stock. The agreement and plan of merger
Under the terms of the agreement, Pharmacyclics has acquired Celera technology and intellectual property relating to drugs that target histone deacetylase (HDAC) enzymes, selective HDAC enzymes, angiogenesis molecules
The company said that patient screening and enrollment for the first of two human trials designed to determine the safety pharmacokinetics of QR-333 will begin immediately. A phase
Results of the primary endpoint for this trial, eight-hour wake after sleep onset (WASO), which is an objective measure of sleep maintenance using polysomnography in a sleep laboratory
Approximately 50% of the Israel Ministry of Industry and Trade funding is designated for R&D expenditures within Israel and 50% is designated for international expenditures. A portion of
MedPharm aims to reduce onset of action to less than 30 minutes through nasal delivery of a reformulated benzodiazepine compared with the one to two hours taken by
The application is based upon the safety and efficacy results of two large randomized pivotal phase III special protocol assessment trials, North American Trial MM-009 and International Trial
The additional shares brings Wyeth’s stake in the company to 80%. Financial terms of the deal were not disclosed. According to Wyeth, growth of Wyeth KK (WKK) is
According to Schering-Plough which markets the drug in the US, Avelox monotherapy at 400mg once daily is as effective as the high-dose combination of 500mg of levofloxacin taken
Under the terms of the agreement, the university (UCSF) is granted a limited license to utilize Sunesis’ fragment-based drug discovery technology Tethering, for academic purposes. UCSF intends to